Picture of Amphastar Pharmaceuticals logo

AMPH Amphastar Pharmaceuticals Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid CapContrarian

Annual cashflow statement for Amphastar Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line1.163.391.4138160
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items227.4817.74129.1
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital9.13-1.92-32.2-24.2-14.5
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Payable / Accrued Expenses
Change in Taxes Payable
Net Change in Other Assets & Liabilities
Cash from Operating Activities57.39889.2184213
Capital Expenditures-33.9-27.5-24-38.2-41
Purchase of Fixed Assets
Other Investing Cash Flow Items-2.56-1.22-8.74-611-83.9
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Cash from Investing Activities-36.4-28.7-32.8-649-125
Financing Cash Flow Items-0.106-56.2-0.407-25.1-0.816
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-2.25-37-26.4454-81
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash1932.129.7-11.87.31